세로토닌-노르에피네프린 재흡수 억제제(SNRI) 시장 : 용도별, 유통 채널별, 지역별

Serotonin Norepinephrine Inhibitor Market is estimated to be valued at USD 7.13 Bn in 2026 and is expected to reach USD 9.64 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.

A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) is a class of medications typically used as antidepressants in the treatment of major depressive disorder (MDD) and other mood disorders. SNRIs work by inhibiting the reuptake of two important neurotransmitters in the brain - serotonin and norepinephrine. By blocking the reabsorption (reuptake) of these neurotransmitters into the neurons, SNRIs increase the levels and enhance the actions of serotonin and norepinephrine in the brain. Serotonin is involved in mood, emotion, and sleep. Norepinephrine is related to alertness and energy. Increasing the amount of these neurotransmitters improves communication between the brain cells and can have a positive impact on mood and emotion, which is beneficial for patients suffering from depression.

Some commonly prescribed SNRIs include:-

• Venlafaxine (Effexor XR)
• Duloxetine (Cymbalta)
• Desvenlafaxine (Pristiq)
• Levomilnacipran (Fetzima)

SNRIs are also approved to treat other conditions such as anxiety disorders, chronic pain conditions like fibromyalgia, and neuropathic pain associated with diabetes.

Market Dynamics:

Rising number of people suffering from depression globally is a major factor driving the market growth of the global serotonin norepinephrine inhibitor market. According to World Health Organization (WHO), over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the near future, due to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also driving the growth of this market. The emergence of COVID-19 pandemic increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people which in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth of the global serotonin norepinephrine inhibitor market.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

• Global Serotonin Norepinephrine Inhibitor Market, By Application (Revenue, USD Bn, 2021 - 2033)
• Depression
• Anxiety Disorders
• Chronic Pain
• Diabetic Neuropathy
• Others
• Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Global Serotonin Norepinephrine Inhibitor Market
• Pfizer Inc.
• Eli Lilly and Company
• Allergan Plc.
• AstraZeneca Plc.
• Forest Laboratories Inc.
• Johnson & Johnson
• Lundbeck A/S
• Merck & Co., Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Wyeth Pharmaceuticals Inc.
• Zydus Cadila Healthcare Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Application
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Increase prevalence of depression and anxiety disorders
    • Availability of new and improved drugs
  • Restraints
    • Side effects
  • Opportunities
    • Increasing adoption of telemedicine
• Key Highlights
• Regulatory Scenario
• Recent trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions and Collaborations

4. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2021-2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Depression
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Anxiety Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Chronic Pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Diabetic Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, For Sub-region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Sub-region, 2022 - 2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Company Profile
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Allergan Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Forest Laboratories Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Lundbeck A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Otsuka Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Torrent Pharmaceuticals Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Wyeth Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Zydus Cadila Healthcare Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
• Analysts' Views

8. Section

• References
• Research Methodology
• About us